Abstract
The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.
Keywords: COVID-19 pandemic; Microneutralization assay; Neutralizing antibodies; SARS-CoV-2; SARS-CoV-2 vaccine; Vaccine effectiveness.
【저자키워드】 SARS-CoV-2, Neutralizing antibodies, COVID-19 pandemic, SARS-CoV-2 vaccine, Microneutralization assay, vaccine effectiveness., 【초록키워드】 COVID-19, Vaccine, Neutralizing antibodies, COVID-19 pandemic, variant, Delta, variants, SARS-CoV-2 vaccine, BNT162b2, Neutralizing activity, Ad26.COV2.S, Microneutralization assay, SARS-CoV-2 antibody, SARS-CoV-2 variants, Effectiveness, ChAdOx1, Pfizer-BioNTech, AstraZeneca, Neutralizing antibody response, ChAdOx1 nCoV-19, BBIBP-CorV, microneutralization, Sinopharm, janssen, Diversity, B.1, lead, vaccine-induced antibodies, participant, neutralizing antibody responses, Ad26, while, variants of SARS-CoV-2, effective, new SARS-CoV-2, collected, was determined, elicited, the SARS-CoV-2, vaccine-induced antibody, 【제목키워드】 Vaccine, omicron, Humoral immunity, outbreak, induced, variants of SARS-CoV-2,